The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's drug to treat a type of muscle-weakening ...

Health and Human Services employees were told in March to remove 'nicknames' from email systems and signatures to comply with ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

British animal genetics company Genus on Wednesday said the U.S. Food and Drug Administration (FDA) approved its PRP gene ...

Zevaskyn is the first and only autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa ...

Bread and rolls sold in six states have been recalled over 'glass fragments,' according to the U.S. Food and Drug ...

AI is a transformational force in healthcare, but without cybersecurity as its foundation, it becomes a high-stakes gamble.

As food companies face pressure to eliminate artificial dyes, experts weigh in on the natural alternatives that could replace ...

IMAAVY TM (nipocalimab-aahu) is a first-in-class FcRn (neonatal Fc receptor) inhibitor, designed to reduce the levels of ...

Pesticides, herbicides, insecticides, preservatives, toxic heavy metals like lead and mercury: Are micropoisons real—and dangerous? Experts reveal the truth.

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

The company has predicted that Imaavy — now approved for generalized myasthenia gravis — could eventually earn more than $5 ...